Khan Nida, Wickman Marie, Schultz Inkeri
From the Division of Reconstructive Plastic Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Reconstructive Plastic Surgery, Karolinska University Hospital, Stockholm, Sweden.
Plast Reconstr Surg Glob Open. 2024 Jul 2;12(7):e5951. doi: 10.1097/GOX.0000000000005951. eCollection 2024 Jul.
Acellular dermal matrices (ADMs) are sometimes used in implant-based breast reconstructions (IBR), but long-term ADM-related evaluations are scarce. In this study, we evaluated early and late complications and patient-related outcomes (PROs) over an 8-year postoperative period in women who had undergone immediate IBR following risk-reducing mastectomy with bovine ADM (SurgiMend).
This prospective observational single-center analysis involved 34 women at high risk for breast carcinoma. Complications were prospectively recorded during the first year, followed by 4 years of postoperative retrospective chart reviews. Long-term evaluations were done using a questionnaire. Preoperative, 1 year, and 5- to 8-year postoperative PRO assessments were obtained based on results from the BREAST-Q questionnaire.
In 56 breasts, complications after a mean of 12.4 months follow-up included implant loss (7.1%), implant change (1.8%), hematoma (7.1%), breast redness (41.1%), and seroma (8.9%). Most breasts (80.3%) were graded Baker I/II, which indicated a low capsular contracture incidence. After a mean of 6.9 years, the total implant explantation rate was 33.9%, and the revision surgery rate was 21.4%. Two cases of breast cancer were reported during the long-term evaluation. BREAST-Q results indicated significantly decreased satisfaction with outcome ( = 0.024). A positive trend regarding psychosocial well-being and declining trend regarding satisfaction with both breast physical- and sexual well-being parameters were reported.
The observed complication rates agree with previous findings concerning ADM-assisted IBR. A high demand for revision surgery exists, and PROs remain relatively stable over time.
脱细胞真皮基质(ADM)有时用于基于植入物的乳房重建(IBR),但与ADM相关的长期评估较少。在本研究中,我们评估了接受降低风险的乳房切除术后立即使用牛ADM(SurgiMend)进行IBR的女性在术后8年期间的早期和晚期并发症以及患者相关结局(PRO)。
这项前瞻性观察性单中心分析纳入了34名乳腺癌高危女性。在第一年对并发症进行前瞻性记录,随后进行4年的术后回顾性病历审查。长期评估通过问卷调查进行。基于BREAST-Q问卷的结果获得术前、术后1年以及术后5至8年的PRO评估。
在56个乳房中,平均随访12.4个月后的并发症包括植入物丢失(7.1%)、植入物更换(1.8%)、血肿(7.1%)、乳房发红(41.1%)和血清肿(8.9%)。大多数乳房(80.3%)为贝克I/II级,表明包膜挛缩发生率较低。平均6.9年后,总植入物取出率为33.9%,翻修手术率为21.4%。在长期评估期间报告了2例乳腺癌病例。BREAST-Q结果表明对结局的满意度显著降低(P = 0.024)。报告了心理社会幸福感呈积极趋势,而对乳房身体和性幸福感参数的满意度呈下降趋势。
观察到的并发症发生率与先前关于ADM辅助IBR的研究结果一致。翻修手术的需求较高,并且PRO随时间保持相对稳定。